These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28274636)

  • 1. Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture.
    Liu CC; Wu SC; Wu SR; Lin HY; Guo MS; Yung-Chih Hu A; Chow YH; Chiang JR; Shieh DB; Chong P
    Vaccine; 2018 May; 36(22):3134-3139. PubMed ID: 28274636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology.
    Yang YT; Chow YH; Hsiao KN; Hu KC; Chiang JR; Wu SC; Chong P; Liu CC
    Antiviral Res; 2016 Aug; 132():225-32. PubMed ID: 27387826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivated Enterovirus 71 Vaccine Produced by 200-L Scale Serum-Free Microcarrier Bioreactor System Provides Cross-Protective Efficacy in Human SCARB2 Transgenic Mouse.
    Wu CY; Lin YW; Kuo CH; Liu WH; Tai HF; Pan CH; Chen YT; Hsiao PW; Chan CH; Chang CC; Liu CC; Chow YH; Chen JR
    PLoS One; 2015; 10(8):e0136420. PubMed ID: 26287531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development.
    Wu SC; Liu CC; Lian WC
    Vaccine; 2004 Sep; 22(29-30):3858-64. PubMed ID: 15364432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates.
    Chou AH; Liu CC; Chang CP; Guo MS; Hsieh SY; Yang WH; Chao HJ; Wu CL; Huang JL; Lee MS; Hu AY; Lin SC; Huang YY; Hu MH; Chow YH; Chiang JR; Chang JY; Chong P
    PLoS One; 2012; 7(4):e34834. PubMed ID: 22529942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of a mink enteritis vaccine production process in stirred-tank reactor and Wave Bioreactor microcarrier culture in 1-10 L scale.
    Hundt B; Best C; Schlawin N; Kassner H; Genzel Y; Reichl U
    Vaccine; 2007 May; 25(20):3987-95. PubMed ID: 17391818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The stability and immunogenicity of formalin-inactivated Enterovirus A71 whole virion vaccine after ten years of low temperature storage.
    Shen YS; Chow YH; Fang CY; Wu SR; Chen CH; Huang MH; Liao CL; Chiang JR; Liu CC
    J Microbiol Immunol Infect; 2023 Dec; 56(6):1121-1128. PubMed ID: 37919172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles.
    Liu CC; Guo MS; Wu SR; Lin HY; Yang YT; Liu WC; Chow YH; Shieh DB; Wang JR; Chong P
    Antiviral Res; 2016 May; 129():58-66. PubMed ID: 26899790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture.
    Liu CC; Lian WC; Butler M; Wu SC
    Vaccine; 2007 Jan; 25(1):19-24. PubMed ID: 16919374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate.
    Tsai YH; Huang SW; Hsieh WS; Cheng CK; Chang CF; Wang YF; Wang JR
    J Virol; 2019 Jul; 93(13):. PubMed ID: 30996087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is a multivalent hand, foot, and mouth disease vaccine feasible?
    Klein M; Chong P
    Hum Vaccin Immunother; 2015; 11(11):2688-704. PubMed ID: 26009802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically isolated enterovirus A71 subgenogroup C4 strain with lethal pathogenicity in 14-day-old mice and the application as an EV-A71 mouse infection model.
    Xu Y; Ma S; Zhu L; Huang Z; Chen L; Xu Y; Yin H; Peng T; Wang Y
    Antiviral Res; 2017 Jan; 137():67-75. PubMed ID: 27864074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Enterovirus 71 Protein Displayed on the Surface of Saccharomyces cerevisiae as an Oral Vaccine.
    Zhang C; Wang Y; Ma S; Li L; Chen L; Yan H; Peng T
    Viral Immunol; 2016 Jun; 29(5):288-95. PubMed ID: 27259043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing, China.
    Wang X; An Z; Huo D; Jia L; Li J; Yang Y; Liang Z; Wang Q; Wang H
    Hum Vaccin Immunother; 2019; 15(5):1183-1190. PubMed ID: 30779680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates.
    Lim PY; Hickey AC; Jamiluddin MF; Hamid S; Kramer J; Santos R; Bossart KN; Cardosa MJ
    Vaccine; 2015 Nov; 33(44):6017-24. PubMed ID: 26271825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases.
    Mao Q; Wang Y; Bian L; Xu M; Liang Z
    Emerg Microbes Infect; 2016 Jul; 5(7):e75. PubMed ID: 27436364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Attenuated Enterovirus A71 Mutant with VP1-V238A,K244R Exhibits Reduced Efficiency of Cell Entry/Exit and Augmented Binding Affinity to Sulfated Glycans.
    Meng T; Wong SM; Chua KB
    J Virol; 2021 Oct; 95(22):e0105521. PubMed ID: 34468173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-clinical safety assessment of repeated intramuscular administration of an EV-A71 VLP vaccine in rabbits.
    Salmons B; Lim PY; Djurup R; Cardosa J
    Vaccine; 2018 Oct; 36(45):6623-6630. PubMed ID: 30293762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MA104 Cell line presents characteristics suitable for enterovirus A71 isolation and proliferation.
    Li ZH; Yue YY; Li P; Song NN; Li B; Zhang Y; Meng H; Jiang GS; Qin L
    Microbiol Immunol; 2015 Aug; 59(8):477-82. PubMed ID: 26138857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system.
    Liu CC; Guo MS; Lin FH; Hsiao KN; Chang KH; Chou AH; Wang YC; Chen YC; Yang CS; Chong PC
    PLoS One; 2011; 6(5):e20005. PubMed ID: 21603631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.